Article

Trial of CRP Inhibitor for RA Halted

Isis Pharmaceuticals has announced that it is halting a trial of its experimental rheumatoid arthritis drug ISIS-CRP due to lack of significant efficacy compared to placebo in Phase II trials.

Isis Pharmaceutical has announced that it is halting a trial of its experimental rheumatoid arthritis (RA) drug ISIS-CRP, due to lack of significant efficacy compared to placebo in Phase II trials. The drug targets C-reactive protein (CRP), which is associated with inflammation.

The Phase IIrandomized, placebo-controlled, trial involved 51 RA patients with chronically elevated CRP, who received 100 mg, 200 mg or 400 mg doses of the experimental drug or placebo for 12 weeks. ISIS-CRP produced dose-dependent reductions in CRP early in treatment as well as improvents in as ACR20 and ACR50 scores measuring RA activity.

However, the responses were not significantly better than those in the placebo group.

The drug continues to be tested as a treatment for atrial fibrillation.

Related Videos
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.